

11.01



[jioh]:Article for revision:jioh\_188\_19

Inbox



Journal of International Or... 22 Jul 2019

to me



If you cannot see this page properly, please [click here](#).

Dear Dr. Rizqiawan

With reference to your manuscript entitled 'Recombinant Protein Galectin-1 Exposure To OM-1 Cell Proliferation', please review the comments of the referees from our site <http://www.journalonweb.com/jioh>. The manuscript would be reconsidered after requisite modifications as per the comments and instructions provided by the **journal**.

If you wish to continue with the publication process, kindly make the changes according to the comments and upload the revised manuscript along with clarifications for all the comments clearly indicating the areas where the changes have been made. Do check the FAQ regarding replying to the comments and uploading a file. The contributors' form/images should be sent separately to the Administrative Office of the **journal**.

The **journal** allows four weeks for the revision of the manuscript. If we do not hear from you within this period, we will consider it as your decision to withdraw your article from publication. Please also note that submission of the revised article does not guarantee its final acceptance by the **journal**.

We thank you for submitting your valuable research work to **Journal of International Oral Health**.

With warm personal regards,



11.01



[jioh]:Acknowledgment for revised manuscript:jioh\_188\_19

Inbox



Journal of International Or... 22 Jul 2019

to me



If you cannot see this page properly, please [click here](#).

Manuscript no.: jioh\_188\_19

Dear Dr. Rizqiawan

**Journal of International Oral Health** has received your revised manuscript entitled 'Recombinant Protein Galectin-1 Exposure To OM-1 Cell Proliferation.' The manuscript will be re-evaluated by concerned referees for the final decision regarding its suitability for publication. We will get back to you within four weeks.

We thank you for submitting your valuable research work to **Journal of International Oral Health**.

With warm personal regards,

The Editorial Team

**Journal of International Oral Health**

Message sent on Monday, July 22, 2019

Please add [editor@jioh.org](mailto:editor@jioh.org) as a contact in your E-mail client to ensure that this mail is not considered as a junk mail.

----- END OF MESSAGE -----

Reply

Forward





Journal of International O... 14 Oct 2019

to me ▾



If you cannot see this page properly, please [click here](#).

Dear Dr. Rizqiawan,

With reference to your manuscript entitled 'Recombinant Protein Galectin-1 Exposure To OM-1 Cell Proliferation', please review the comments of the referees from our site <http://www.journalonweb.com/jioh>. The manuscript would be reconsidered after requisite modifications as per the comments and instructions provided by the journal.

If you wish to continue with the publication process, kindly make the changes according to the comments and upload the revised manuscript along with clarifications for all the comments, clearly indicating the areas where the changes have been made. Do check the FAQ related to responding to the comments and uploading a revised file. The contributors' form/images should be sent separately to the Administrative Office of the journal.

The journal allows two weeks for the revision of the manuscript. If we do not hear from you within this period, we will consider it as your decision to withdraw your article from publication. Please also note that submission of the revised article does not guarantee its final acceptance by the journal.

We thank you for submitting your valuable research work to Journal of International Oral Health.

With warm personal regards,

...

Reply

Forward



## Original Research

Deleted: Article

Formatted: Not Highlight

## Recombinant Protein Galectin-1 Exposure to OM-1 Cell

Deleted: To

## Proliferation: An *In Vitro* Study

Rizqiawan, *et al.*: Recombinant galectin-1 to cell proliferation

Deleted: Recombinant Protein Galectin-1 Exposure To OM-1 Cell Proliferation: An In Vitro Study<sup>4</sup>

Rizqiawan, et al.: Recombinant galectin-1 to cell proliferation

Formatted: Not Highlight

**Andra Rizqiawan, Indra Mulyawan, Aries Muharram, Ni Putu Mira Sumarta,**

Deleted: Recombinant Protein Galectin-1 Exposure To OM-1 Cell Proliferation: An In Vitro Study<sup>4</sup>

Formatted: Not Highlight

**David B. Kamadjaja, Coen P. Danudiningrat**

Formatted

... [1]

Department of Oral and Maxillofacial Surgery, Faculty of Dental Medicine, Universitas

Deleted: untoro

Formatted

... [2]

Airlangga, Surabaya, Indonesia

Deleted: ramono

Formatted: Font color: Auto

Address for correspondence: Dr. Andra Rizqiawan, Department of Oral and

Formatted

... [3]

Maxillofacial Surgery, Faculty of Dental Medicine, Universitas Airlangga Jl. Prof. Dr.

Formatted

... [4]

Moestopo 47, Surabaya, 60132, Indonesia

Commented [NG1]: [AU: Department, Faculty and University names have been included in the Address for correspondence. Please confirm.]

Formatted: Font color: Dark Red

E-mail: andra-r@fkg.unair.ac.id

Deleted: - Indonesia,

Formatted: Font color: Dark Red

How to cite this article: Rizqiawan A, Mulyawan I, Muharram A, Sumarta Ni Putu

Deleted: address: andra-r@fkg.unair.ac.id

... [5]

Formatted: Font color: Dark Red

Mira, Kamadjaja DB, Danudiningrat CP. Recombinant protein galectin-1 exposure to

Formatted

... [6]

OM-1 cell proliferation: An *in vitro* study. J Int Oral Health 2019;XX:XX-XX.

Deleted: XXX;...X...X-X

... [7]

Submission: 21-07-19

Formatted: Font color: Auto

Review completed: XX-XX-XX

Formatted: Font color: Auto

Accepted: XX-XX-XX

Formatted: Font color: Auto

Formatted: ¶FM\_MSHistory

Formatted: Font: 14 pt, Font color: Blue, Not Small caps

## Abstract

Deleted: ¶  
Background: Galectin-1 (Gal-1) is a 14-kDa laminin-binding galectin involved in several biological events, including the regulation of tumor proliferation and metastasis. Gal-1 is highly expressed in the invasive front of primary tumors. OM-1 cell constitutes a low invasive oral squamous cell carcinoma with limited Gal-1 protein expression....

Formatted

... [8]

**Aims and Objectives:** The aim of this study was to overcome the shortage of galectin-1 (Gal-1) protein, and to determine cell proliferation by adding recombinant protein that has a high protein content of the squamous cell OM-1.

**Materials and Methods:** A presented study was randomized controlled trial. The role of recombinant protein galectin-1 (r-Gal-1) in combating squamous cell carcinoma of the OM-1, as compared to HOC313 squamous cell carcinoma without exposure to r-Gal-1, through the promotion of cell proliferation. An *in vitro* experiment was conducted on the following three groups: a negative control group using OM-1 cells, an intervention group comprising OM-1 cells to which 8 µg/mL r-Gal-1 was added, and a positive control incorporating HOC313 cells that were highly invasive. The proliferation level of the cells was measured by means of the optical density on a microplate reader on days 0, 1, 2, 3, and 4. In the three test groups, an increased proliferation rate was obtained on days 1, 2, 3, and 4 on OM-1, OM-1 + r-Gal-1, and HOC313. The statistical analysis was carried out using analysis of variance test, Kruskal-Wallis test, least significant difference test, and Mann-Whitney test.

**Results:** The proliferation rate increased significantly ( $P < 0.05$ ) in the treatment group (OM-1 + r-Gal-1) as compared to the negative control group (OM-1). The positive control group (HOC313) experienced the highest degree of proliferation among the three groups.

**Conclusion:** Gal-1 is a protein, that plays a key role in the processes of cancer metastasis and invasion.

**Keywords:** OM-1, Optical density, Oral squamous cell carcinoma, Proliferation, Recombinant protein galectin-1

**Commented [NG2]:** [AU: As per journal style, only four subheadings: "Aims and Objectives, Materials and Methods, Results, Conclusion" are allowed in Abstract. Thus, "Background" has been deleted and "Aims" has been modified to "Aims and Objectives" in line with this. Please confirm.]

**Commented [NG3]:** [AU: Please check the edits made to the sentence "The aim of this study was to overcome the shortage of galectin-1 (Gal-1) protein and to determine cell proliferation by adding" for accuracy.]

**Formatted:** Font color: Dark Gray

**Formatted:** Font color: Dark Gray

**Deleted:** To to overcome the shortage of galectin-1 (gal...al-1) protein, ... and recombinant protein was added ... [9]

**Formatted:** Font: 12 pt, Font color: Dark Gray

**Commented [NG4]:** [AU: Please consider rephrasing the sentence "A presented study was randomized controlled trial. The role of recombinant protein galectin-1 (r-Gal-1) in combating ..." for clarity.]

**Deleted:** Methods and

**Formatted:** Font color: Dark Gray

**Formatted:** ... [10]

**Deleted:** combating

**Commented [NG5]:** [AU: Please consider rephrasing the sentence "The role of recombinant protein galectin-1 (r-Gal-1) in combating squamous cell carcinoma of the OM-1, as compared to HOC313 squamous cell carcinoma without exposure to r-Gal-1, through the promotion ..." for clarity.]

**Formatted:** ... [11]

**Deleted:** \*

**Formatted:** ... [12]

**Deleted:** containing comprising OM-1 cells to which 8 µg/ml ... L recombinant protein galectin-1r-Gal-1 had been ... as added, and a positive control incorporating HOC313 cells which ... hat are ... ere highly invasive. The proliferation level of the cells was measured by means of the optical density on a micro ... late reader on days 0, 1, 2, 3, and 4. In the three test groups, an increased proliferation rate was obtained on days 1, 2, 3, and 4 on OM-1, OM-1 + r-Gal-1 recombinant protein galectin-1... and HOC313. The statistical... [13]

**Formatted:** ... [14]

**Deleted:** p < 0

**Deleted:** recombinant protein gal-1) as compared to the negative... [15]

**Commented [NG6]:** [AU: Please check the edits made to the... [16]

**Formatted:** Font: 12 pt, Font color: Dark Gray

**Deleted:** s

**Formatted:** Font color: Dark Gray

**Deleted:** The ... al-1 is one of the ... proteins ... [17]

**Formatted:** ... [18]

**Deleted:** o

**Formatted:** Font color: Auto

**Deleted:** OM-1, p

**Formatted:** ... [19]

**Deleted:** r

## INTRODUCTION

Cancer, whose global incidence is increasing due to lifestyle changes, ranks the second most common cause of death following cardiovascular diseases and affects all levels of society. Oral cancer ranks as the sixth leading type cancer globally and accounts for more than 90% of squamous cell carcinoma.<sup>[1]</sup> The factors responsible for this type of oral cancer can be either intrinsic or extrinsic. The intrinsic factors comprise general malnutrition or anemia due to iron deficiency, whereas the extrinsic factors comprise smoking, alcohol, chewing betel nut, and genotype infection by the human papillomavirus (HPV). Diets low in fresh fruit and vegetables have recently been found as risk factors for an individual developing squamous cell carcinoma.<sup>[2]</sup>

Cancers originating in the epithelial tissue are referred to as carcinomas. Squamous cell carcinoma, a malignant tumor derived from epithelium tissue with cell structure group, is able to spread throughout the body via the bloodstream and lymphatic system. Squamous cell carcinoma is the most common form of malignancy affecting the oral cavity at approximately 90%–95% of malignant neoplasms of the oral cavity. It is usually located on the tongue ventral and lateral, lips, mouth floor, buccal mucosa, and retromolar regions.<sup>[3]</sup> Squamous cell carcinoma of the oral cavity remains a significant cause of death worldwide with approximately 500,000 new cases being diagnosed annually.<sup>[4]</sup>

In 2011, it was estimated that more than 11,460 deaths resulted from head and neck squamous cell carcinoma in the United States and over 300,000 deaths globally. The majority of the patients presented stage III/IV head and neck squamous cell carcinoma, and only approximately 40% of the patients received a prognosis of survival beyond 5

Formatted: Font color: Blue

Formatted: Font color: Auto

Deleted: only to cardiovascular disease as a

Deleted:

Deleted: most common type

Deleted: with

Deleted: constituting

Formatted: Font color: Auto, Not Superscript/ Subscript, Border: : (No border)

Deleted: Contributory

Deleted: to

Deleted: form

Deleted: in character

Deleted: I

Deleted: can include

Deleted: A d

Deleted: fresh

Deleted: has

Deleted: to carry a

Deleted: significant risk of

Formatted: Font color: Auto, Not Superscript/ Subscript, Border: : (No border)

Deleted: represents

Deleted: total

Deleted: cases of malignancy

Deleted: in addition to the

Deleted: in the

Formatted: Font color: Auto, Not Superscript/ Subscript, Border: : (No border)

Deleted: It is estimated that, in

Formatted: Font color: Auto, Not Superscript/ Subscript, Border: : (No border)

Deleted: ,

Deleted: in the United States

Deleted: of the head and

Deleted: neck

Deleted: , while the global total exceeded

Deleted: ,

Deleted:

Deleted:

Deleted: of the head and neck

Deleted: five

<b>Page 1: [1] Formatted</b>	<b>Newgen</b>	<b>12/4/19 8:53:00 AM</b>
Font color: Auto, Pattern: Clear		
<b>Page 1: [1] Formatted</b>	<b>Newgen</b>	<b>12/4/19 8:53:00 AM</b>
Font color: Auto, Pattern: Clear		
<b>Page 1: [1] Formatted</b>	<b>Newgen</b>	<b>12/4/19 8:53:00 AM</b>
Font color: Auto, Pattern: Clear		
<b>Page 1: [1] Formatted</b>	<b>Newgen</b>	<b>12/4/19 8:53:00 AM</b>
Font color: Auto, Pattern: Clear		
<b>Page 1: [1] Formatted</b>	<b>Newgen</b>	<b>12/4/19 8:53:00 AM</b>
Font color: Auto, Pattern: Clear		
<b>Page 1: [1] Formatted</b>	<b>Newgen</b>	<b>12/4/19 8:53:00 AM</b>
Font color: Auto, Pattern: Clear		
<b>Page 1: [1] Formatted</b>	<b>Newgen</b>	<b>12/4/19 8:53:00 AM</b>
Font color: Auto, Pattern: Clear		
<b>Page 1: [2] Formatted</b>	<b>Newgen</b>	<b>12/4/19 8:53:00 AM</b>
Font color: Auto		
<b>Page 1: [2] Formatted</b>	<b>Newgen</b>	<b>12/4/19 8:53:00 AM</b>
Font color: Auto		
<b>Page 1: [3] Formatted</b>	<b>Newgen</b>	<b>12/4/19 8:53:00 AM</b>
Font color: Auto		
<b>Page 1: [3] Formatted</b>	<b>Newgen</b>	<b>12/4/19 8:53:00 AM</b>
Font color: Auto		
<b>Page 1: [3] Formatted</b>	<b>Newgen</b>	<b>12/4/19 8:53:00 AM</b>
Font color: Auto		
<b>Page 1: [3] Formatted</b>	<b>Newgen</b>	<b>12/4/19 8:53:00 AM</b>
Font color: Auto		
<b>Page 1: [3] Formatted</b>	<b>Newgen</b>	<b>12/4/19 8:53:00 AM</b>
Font color: Auto		
<b>Page 1: [4] Formatted</b>	<b>Newgen</b>	<b>12/4/19 8:53:00 AM</b>
Font color: Dark Red		
<b>Page 1: [4] Formatted</b>	<b>Newgen</b>	<b>12/4/19 8:53:00 AM</b>
Font color: Dark Red		
<b>Page 1: [4] Formatted</b>	<b>Newgen</b>	<b>12/4/19 8:53:00 AM</b>
Font color: Dark Red		
<b>Page 1: [5] Deleted</b>	<b>Newgen</b>	<b>12/4/19 10:01:00 AM</b>

x

**Page 1: [5] Deleted** **Newgen** **12/4/19 10:01:00 AM**

x

**Page 1: [6] Formatted** **Newgen** **12/4/19 8:53:00 AM**

Font color: Dark Red

**Page 1: [6] Formatted** **Newgen** **12/4/19 8:53:00 AM**

Font color: Dark Red

**Page 1: [6] Formatted** **Newgen** **12/4/19 8:53:00 AM**

Font color: Dark Red

**Page 1: [6] Formatted** **Newgen** **12/4/19 8:53:00 AM**

Font color: Dark Red

**Page 1: [6] Formatted** **Newgen** **12/4/19 8:53:00 AM**

Font color: Dark Red

**Page 1: [7] Deleted** **Newgen** **12/3/19 6:46:00 PM**

x

**Page 1: [7] Deleted** **Newgen** **12/3/19 6:46:00 PM**

x

**Page 1: [7] Deleted** **Newgen** **12/3/19 6:46:00 PM**

x

**Page 1: [7] Deleted** **Newgen** **12/3/19 6:46:00 PM**

x

**Page 1: [8] Formatted** **Newgen** **12/4/19 8:53:00 AM**

Not Small caps

**Page 1: [8] Formatted** **Newgen** **12/4/19 8:53:00 AM**

Not Small caps

**Page 2: [9] Deleted** **Newgen** **12/4/19 8:20:00 AM**

x

**Page 2: [9] Deleted** **Newgen** **12/4/19 8:20:00 AM**

x

**Page 2: [9] Deleted** **Newgen** **12/4/19 8:20:00 AM**

x



**Page 2: [9] Deleted** **Newgen** **12/4/19 8:20:00 AM**

x

**Page 2: [10] Formatted** **Newgen** **12/4/19 8:53:00 AM**

Font: 12 pt, Font color: Dark Gray

**Page 2: [10] Formatted** **Newgen** **12/4/19 8:53:00 AM**

Font: 12 pt, Font color: Dark Gray

**Page 2: [10] Formatted** **Newgen** **12/4/19 8:53:00 AM**

Font: 12 pt, Font color: Dark Gray

**Page 2: [11] Formatted** **Newgen** **12/4/19 8:53:00 AM**

Font: 12 pt, Font color: Dark Gray

**Page 2: [11] Formatted** **Newgen** **12/4/19 8:53:00 AM**

Font: 12 pt, Font color: Dark Gray

**Page 2: [12] Formatted** **Newgen** **12/4/19 8:53:00 AM**

Font: 12 pt, Font color: Dark Gray

**Page 2: [12] Formatted** **Newgen** **12/4/19 8:53:00 AM**

Font: 12 pt, Font color: Dark Gray

**Page 2: [12] Formatted** **Newgen** **12/4/19 8:53:00 AM**

Font: 12 pt, Font color: Dark Gray

**Page 2: [13] Deleted** **Newgen** **12/3/19 9:50:00 PM**

x

**Page 2: [13] Deleted** **Newgen** **12/3/19 9:50:00 PM**

x

**Page 2: [13] Deleted** **Newgen** **12/3/19 9:50:00 PM**

x

**Page 2: [13] Deleted** **Newgen** **12/3/19 9:50:00 PM**

x

**Page 2: [13] Deleted** **Newgen** **12/3/19 9:50:00 PM**

x

**Page 2: [13] Deleted** **Newgen** **12/3/19 9:50:00 PM**

x

**Page 2: [13] Deleted** **Newgen** **12/3/19 9:50:00 PM**

x

**Page 2: [13] Deleted** **Newgen** **12/3/19 9:50:00 PM**

x

**Page 2: [13] Deleted** **Newgen** **12/3/19 9:50:00 PM**

x

**Page 2: [13] Deleted** **Newgen** **12/3/19 9:50:00 PM**

x

**Page 2: [13] Deleted** **Newgen** **12/3/19 9:50:00 PM**

x

**Page 2: [13] Deleted** **Newgen** **12/3/19 9:50:00 PM**

x

**Page 2: [13] Deleted** **Newgen** **12/3/19 9:50:00 PM**

x

**Page 2: [14] Formatted** **Newgen** **12/4/19 8:53:00 AM**

Font color: Dark Gray

**Page 2: [14] Formatted** **Newgen** **12/4/19 8:53:00 AM**

Font color: Dark Gray

**Page 2: [14] Formatted** **Newgen** **12/4/19 8:53:00 AM**

Font color: Dark Gray

**Page 2: [15] Deleted** **Newgen** **12/4/19 5:01:00 AM**

x

**Page 2: [15] Deleted** **Newgen** **12/4/19 5:01:00 AM**

x

**Page 2: [15] Deleted** **Newgen** **12/4/19 5:01:00 AM**

x

**Page 2: [16] Commented [NG6]** **Newgen** **12/4/19 12:23:00 PM**

[AU: Please check the edits made to the sentence "The positive control group (HOC313) experienced the highest degree of proliferation among the three groups" for accuracy.]

**Page 2: [17] Deleted** **Newgen** **12/4/19 8:26:00 AM**

x .....  
**Page 2: [17] Deleted** **Newgen** **12/4/19 8:26:00 AM**

x .....  
**Page 2: [17] Deleted** **Newgen** **12/4/19 8:26:00 AM**

x .....  
**Page 2: [18] Formatted** **Newgen** **12/4/19 8:53:00 AM**

Font color: Auto

**Page 2: [18] Formatted** **Newgen** **12/4/19 8:53:00 AM**

Font color: Auto

**Page 2: [18] Formatted** **Newgen** **12/4/19 8:53:00 AM**

Font color: Auto

**Page 2: [19] Formatted** **Newgen** **12/4/19 10:43:00 AM**

Font color: Auto

**Page 2: [19] Formatted** **Newgen** **12/4/19 10:43:00 AM**

Font color: Auto

Welcome Andra Rizqlawan Article Cycle Logout

- Home
- Submission
- Downloads
- Symposia
- Submitted manuscript(s)
- Accepted manuscripts
- Personal details
- About us
- Reach us
- Help

Article details...

**Title** Recombinant Protein Galectin-1 Exposure To OM-1 Cell Proliferation: An In Vitro Study

**Type** Original Article

**Submission Date** 21-Jul-19 14:03

**Abstract**  
[Click here to view Abstract](#)

**Subjects**

**Author profiles** [\[View author profiles\]](#)

Your article files...

**First Page File(s)** [jioh\\_188\\_19FP.docx](#) [jioh\\_188\\_19FPR1.docx](#)

**Article File(s)**

1	<a href="#">jioh_188_19.docx</a>	2	<a href="#">JIOH_188_19R1.doc</a>	3	<a href="#">jioh_188_19R2.docx</a>	4	<a href="#">JIOH_188_19R3.docx</a>
5	<a href="#">JIOH_188_19R4.doc</a>	6	<a href="#">JIOH_188_19R5.doc</a>	7	<a href="#">jioh_188_19R6.docx</a>	8	<a href="#">JIOH_188_19R7.docx</a>
9	<a href="#">jioh_188_19R8.docx</a>	10	<a href="#">JIOH_188_19R9.docx</a>	11	<a href="#">jioh_188_19R10.docx</a>	12	<a href="#">jioh_188_19R11.docx</a>
13	<a href="#">jioh_188_19R12.pdf</a>	14	<a href="#">jioh_188_19R13.doc</a>	15	<a href="#">jioh_188_19R14.pdf</a>	16	<a href="#">jioh_188_19R15.doc</a>
17	<a href="#">jioh_188_19R16.pdf</a>	18	<a href="#">jioh_188_19R17.doc</a>	19	<a href="#">jioh_188_19R18.pdf</a>	20	<a href="#">jioh_188_19R19.doc</a>
21	<a href="#">jioh_188_19R20.pdf</a>	22					

**Images** [View Images](#)

**Forms** [View Forms](#)

**CheckList** [View CheckList](#)

- Images [View Images](#)
- Forms [View Forms](#)
- CheckList [View CheckList](#)

Article related...

[Search PubMed](#)  
[Search in Medknow](#)

[View copyright form](#)

Copyright form received  
Images Received

This article is assigned to May-Jun:2020 issue.

Progress of review process...

	Status	Comments	Phase entry date	Days in review
1	Editorial Review	-	21/Jul/19 10:03	--
	--do--	-	21/Jul/19 11:30	0 [0]
3	Under revision	Remark	22/Jul/19 05:19	1 [1]
5	Editorial Review	-	22/Jul/19 08:55	1 [0]
7	Under revision	Remark	23/Jul/19 01:13	2 [1]
9	Peer Review	-	13/Aug/19 08:00	23 [21]
11	Editorial Review	-	20/Aug/19 07:59	30 [7]
13	Editorial review	-	21/Aug/19 06:36	31 [1]
15	Under revision	Remark	21/Aug/19 06:59	31 [0]
17	Editorial Review	-	29/Aug/19 10:29	39 [8]
19	Under revision	Remark	30/Aug/19 01:01	40 [1]
	--do--	Remark	13/Sep/19 07:34	54 [14]
21	Editorial Review	-	18/Sep/19 03:11	59 [5]
23	Under revision	Remark	04/Oct/19 07:45	75 [16]
25	Editorial Review	-	06/Oct/19 21:09	77 [21]

21	Editorial Review	-	18/Sep/19 03:11	59 [5]
23	Under revision	Remark	04/Oct/19 07:45	75 [16]
25	Editorial Review	-	06/Oct/19 21:09	77 [2]
27	Re-revision	Remark	14/Oct/19 05:17	85 [8]
29	Editorial Review	-	26/Oct/19 01:41	97 [12]
31	Re-revision	Remark	01/Nov/19 07:37	103 [6]
33	Editorial Review	-	10/Nov/19 09:52	112 [9]
	--do--	-	12/Nov/19 05:48	114 [2]
36	Editorial review	-	28/Nov/19 08:49	130 [16]
38	Technical check	-	28/Nov/19 10:11	130 [0]
	--do--	-	29/Nov/19 07:30	131 [1]
	--do--	-	05/Dec/19 14:26	137 [6]
42	Accepted	-	09/Dec/19 08:28	141 [4]
44	Under issue preparation	-	09/Dec/19 08:35	141 [0]
	--do--	-	09/Dec/19 09:09	141 [0]
47	For proof check	-	09/Dec/19 10:39	141 [0]
49	Under preparation for issue	-	10/Dec/19 16:02	142 [1]
	--do--	-	12/Dec/19 07:52	144 [2]
	--do--	-	13/Dec/19 06:33	145 [1]
53	For proof check	-	19/Dec/19 06:18	151 [6]
55	Under preparation for issue	-	25/Dec/19 10:26	157 [6]
57	For proof check	-	30/Dec/19 13:24	162 [5]
59	Under preparation for issue	-	05/Jan/20 17:47	168 [6]
	--do--	-	08/Jan/20 08:06	171 [3]

	--do--	-	13/Dec/19 06:33	145 [1]
53	For proof check	-	19/Dec/19 06:18	151 [6]
55	Under preparation for issue	-	25/Dec/19 10:26	157 [6]
57	For proof check	-	30/Dec/19 13:24	162 [5]
59	Under preparation for issue	-	05/Jan/20 17:47	168 [6]
	--do--	-	08/Jan/20 08:06	171 [3]
	--do--	-	10/Jan/20 03:26	173 [2]
63	For proof check	-	14/Jan/20 06:53	177 [4]
65	Under preparation for issue	-	30/Jan/20 05:37	193 [16]
	--do--	-	03/Feb/20 08:19	197 [4]
	--do--	-	04/Feb/20 05:10	198 [1]
69	For proof check	-	07/Feb/20 10:26	201 [3]
71	Under preparation for issue	-	10/Feb/20 17:34	204 [3]
	--do--	-	11/Feb/20 07:20	205 [1]
	--do--	-	11/Feb/20 09:48	205 [0]
75	For proof check	-	14/Feb/20 09:43	208 [3]
77	Under preparation for issue	-	19/Feb/20 15:23	213 [5]
	--do--	-	27/Feb/20 08:31	221 [8]
80	Article published	-	02/Jun/20 10:10	317 [96]
	--do--	-	02/Jun/20 10:10	317 [0]
	--do--	-	22/Jul/20 07:42	367 [50]

